Rapid ReviewLive flavivirus vaccines: reasons for caution
Section snippets
Flaviviruses
The flaviviruses are enveloped positive-sense single-stranded RNA viruses of about 11 kb. Both ends of the genome contain non-translated nucleotides (NTR). The open-reading frame is translated into three structural proteins (core, premembrane, envelope) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5). Some flaviviruses are mosquitoborne, some are tick borne, and others have no known vector.8 The mosquito borne species comprise those transmitted by Culex spp, often with
Recombination
RNA viruses can recombine within and between species, as a result of transfer of RNA polymerase between viral genomes during RNA synthesis. One example is the appearance of western equine encephalitis virus from recombination between two alphaviruses with different pathogenetic characteristics (figure, A).10 Homologous recombination (between strains of the same species) in flaviviruses was firmly established in 1999, and has now been seen in all four dengue serotypes and in Japanese and St
How likely is inter-species flavivirus recombination?
The main requirement for recombination is simultaneous infection with two flaviviruses. Unfortunately the risk of recombination resulting in more virulent virus cannot be quantified. However, the expanding geographic dispersal of flaviviruses greatly increases the chances of natural co-infection. Although low concentrations of blood-borne virus are common in West Nile infection, as in other flavivirus infections in which human beings are normally a dead-end host, a high prevalence of infection
Lessons from other live virus vaccines
Five main problems have been recognised: reversion of vaccine strains to increased virulence; development of disease in immunocompromised individuals; fetal malformation particularly when the vaccine is given in the first trimester; spread of vaccine strains to unvaccinated persons; and the discovery of previously unknown complications. With live poliovirus vaccines, reversion to virulence as a result of recombination,14 disease in immunocompromised recipients (especially in IgA deficiency),15
Assessment
Live virus vaccines offer considerable promise in terms of efficacy and cost. Unfortunately, the risks of recombination between vaccine virus and other wild-type flaviviruses resulting in recombinants with novel properties cannot be estimated. The surprising emergence of western equine encephalitis virus, a non-homologous recombinant estimated to have arisen some 1300 years ago, has had prolonged consequences.32 Reports of the decreased ability of candidate vaccine strains to grow in mosquito3,
References (34)
- et al.
Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys
Vaccine
(2003) - et al.
Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus
Virology
(2003) - et al.
The future of dengue vaccines
Lancet
(2002) - et al.
Tick-borne encephalitis
Antiviral Res
(2003) - et al.
Rarity of adverse effects after 17D yellow-fever vaccination
Lancet
(2001) - et al.
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases
Lancet
(2001) - et al.
Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases
Lancet
(2001) - et al.
Hepatitis and death following vaccination with 17D-204 yellow fever vaccine
Lancet
(2001) - et al.
Effects of yellow fever vaccination
Lancet
(2001) - et al.
Effects of yellow fever vaccination
Lancet
(2001)
Effects of yellow fever vaccination
Lancet
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children
Pediatr InfectDis J
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine
Am J Trop Med Hyg
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development
J Virol
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE)
J Infect Dis
Origins, evolution, and vector/host co-adaptations within the Genus Flavivirus
Adv Vir Res
Western equine encephalitis virus is a recombinant virus
Proc Natl Acad Sci USA
Cited by (99)
Progress and Works in Progress: Update on Flavivirus Vaccine Development
2017, Clinical TherapeuticsCitation Excerpt :A principle determinant of risk is the type of vaccine. YFV vaccine, which is a live-attenuated virus, has rarely caused cases of severe neurotropic and viscerotropic reactions during decades of use,191 and possible teratogenic effects have been investigated. Potential for reversion to wild type or fully virulent virus, pathogenicity in immunocompromised hosts, or recombination events between vaccine and circulating strains that lead to new, deleterious phenotypes have all been put forward as reasons for trepidation with these vaccines,191 although the latter phenomenon has never been observed in nature.13
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines
2017, Biotechnology AdvancesNatural recombination in alphaherpesviruses: Insights into viral evolution through full genome sequencing and sequence analysis
2017, Infection, Genetics and EvolutionCitation Excerpt :The relatively low rate of recombination in VZV compared to HSV-1 may be due to the distinct biology and epidemiology of VZV (Kaufman et al., 2005; Schmidt-Chanasit et al., 2009; Wang et al., 2010) as well as geographical separations of strains (Norberg et al., 2004; Schmidt-Chanasit et al., 2009). However, ongoing monitoring of recombination in field isolates of VZV is needed, as recombination between attenuated viruses such as vaccine strains has been detected, to create recombinant virulent progeny in other alphaherpesviruses (Lee et al., 2012), as well as in several other virus families (Becher et al., 2001; Camus-Bouclainville et al., 2011; Chong et al., 2010; Cuervo et al., 2001; Dahourou et al., 2002; Holmes et al., 1999; Liu et al., 2003; Norberg et al., 2013; Seligman and Gould, 2004; Wenhui et al., 2012). Over the past ten years natural recombination has been assessed in alphaherpesviruses from five non-human mammalian hosts; EHV-1, EHV-4, EHV-9, FeHV-1 and PRV (Greenwood et al., 2012; Pagamjav et al., 2005; Vaz et al., 2016a; Vaz et al., 2016b; Ye et al., 2016) (Table 2).